Physician profile
Jay E Olsson
NPI 1144264904
$6,235.06
in general payments reported to CMS, 2019-2025
38 companies · $572 in 2025
The $572 reported for 2025 was more than what 81% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,231 · 2020: $609 · 2021: $1,126 · 2022: $1,114 · 2023: $995 · 2024: $587 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,154.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $840.16 | 2019-2025 | Xtampza, Belbuca |
| Abbvie INC. | $705.44 | 2021-2024 | |
| Avanir Pharmaceuticals, INC. | $551.42 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $473.33 | 2019-2024 | Ztlido |
| Pfizer INC. | $407.66 | 2019-2024 | |
| Vanda Pharmaceuticals INC. | $339.12 | 2024-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $326.30 | 2020-2025 | Austedo Xr |
| Protega Pharmaceutials INC | $294.01 | 2023-2025 | Roxybond |
| Lilly USA, LLC | $261.26 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $200.69 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $186.12 | 2022 | |
| Allergan, INC. | $166.26 | 2019-2021 | |
| Daiichi Sankyo INC. | $162.57 | 2019 | |
| Biodelivery Sciences International, INC. | $151.63 | 2019-2021 | |
| Almatica Pharma LLC | $130.82 | 2022-2023 | Gralise |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Olsson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.